The Dangers Of CEL-SCI Corporation [Seeking Alpha]
Cel-Sci Corporation (CVM)
NASDAQ:AMEX Investor Relations:
cel-sci.com/investor_relations.html
Company Research
Source: Seeking Alpha
The Dangers Of CEL-SCI Corporation Summary CEL-SCI's move from $3 to $8 on fairly minor news appears exaggerated. Multikine has a several yearlong history of struggling to complete its Phase 3 study. CEL-SCI faces major financial constraints whether Multikine is approved or not. CEL-SCI Corporation ( CVM CVM's latest earnings report Catalyst For CVM's Recent Move On March 29, CVM released a press release shareholder letter Why Investors Should Tread Carefully First, what appears to be the primary catalyst for CVM's move – the IDMC announcing that Phase 3 studies should continue until the appropriate number of events have occurred – is absolutely not an indication that we can expect FDA approval in future, and can only really be interpreted as bullish news if one was worried about the possibility of Multikine being immediately declared futile or unsafe before Phase 3 studies are officially concluded. That is somewhat meaningful (there is always a non-insignificant risk with drugs of th
Show less
Read more
Impact Snapshot
Event Time:
CVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVM alerts
High impacting Cel-Sci Corporation news events
Weekly update
A roundup of the hottest topics
CVM
News
- CEL-SCI files to sell 1M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer PatientsBusiness Wire
- CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerBusiness Wire
- CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation [Yahoo! Finance]Yahoo! Finance
- CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and RadiationBusiness Wire
CVM
Earnings
- 8/14/24 - Miss
CVM
Sec Filings
- 10/30/24 - Form S-3/A
- 10/25/24 - Form S-3
- 10/11/24 - Form POS
- CVM's page on the SEC website